Fig. 7: ESSO9 inhibits angiogenesis in vivo. | Oncogenesis

Fig. 7: ESSO9 inhibits angiogenesis in vivo.

From: A drug-repositioning screen using splicing-sensitive fluorescent reporters identifies novel modulators of VEGF-A splicing with anti-angiogenic properties

Fig. 7

A ESSO9-treated PC3 cells (48 h) were mixed with Matrigel. The Matrigel and control cells were injected subcutaneously into nude mice. Four days post-injection, the plugs were removed and RNA was extracted. B, C Photographs were taken of each plug and colour intensity quantified using ImageJ software. There was a significant reduction in ESSO9 plug intensity. n = 6, P = 0.0002. D RT-PCR for VEGF-A splice variants showed a switch in splicing to increase VEGF-Axxxb isoforms in some ESSO9-treated plugs compared to DMSO controls (n = 3).

Back to article page